Feb. 6 at 1:03 PM
$MGTX I don't believe enough attention (and significance) has been given to the 2 "events" that Meira has announced so far in 2026. Specifically, the ~
$18M share buyback with Perceptive and this week's JV with ZipBio. Here’s why - to boil down the short thesis it's essentially liquidity risk / cash burn and pivotal trial risk for Xerostomia & Parkinson's.
Biotech's (or any companies for that matter), that are facing liquidity concerns do not do share buybacks - EVER. Nor do they do deals to license new assets where an upfront payment is required. Instead they hoard cash and cut the company to the bone.
Meira's 2026 announcements confirm that they have exceedingly high conviction that their valuation will 3-5x larger 12 months from now at which time they'll have plenty of options to raise additional capital with minimal to no shareholder dilution.
